ALSO NOTED: Sanofi sues to fight off Uroxatral imitators; Watson gets OK for generic AccuNeb

> Sanofi Aventis sued two generics makers--Teva Pharmaceuticals and Barr Laboratories--for infringing its patents on the prostate cancer drug Uroxatral. Report

> Watson Pharmaceuticals got the FDA nod for its generic form of the asthma medication AccuNeb. Report

> Sanofi Pasteur is scouting India, among other countries, for possible locations for a global manufacturing base, the Economic Times reports. Report

> AstraZeneca is poised to open an Israeli office and is seeking a local general manager there.  Report

And Finally... Don't count on snagging your daily meds from a pharma facility. The thieves who got out of Genentech with human growth hormone are exceptions to the high-security rule--so much so that one expert likened a drug-company theft to stealing gold from Fort Knox. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.